Structure Therapeutics Inc.

NASDAQ:GPCR

Biotechnology

Healthcare
$17.36 +0.86%

+$0.39 today

Market cap
$999.36M
Beta
-1.42
P/E (TTM)
-19.3
EPS (TTM)
-$2.35
52W Low $15.80High $94.90

Volume 1.10M

Average 0.87M

GPCR Total Debt

Short-term and long-term borrowings combined.

Structure Therapeutics Inc.NASDAQ: GPCR

Total Debt · Q2 FY2026 · quarter ended Jun 2026

Total debt falls 18.9% from a year ago

Total debt stood at $6.23M at the end of Q2 FY2026, down 18.9% from a year earlier and up 7.5% from the prior quarter. Over 3 fiscal years it compounded at +192.2% a year.

Context

  • Total debt amounted to 0.4% of total assets at the end of Q2 FY2026, down 0.5 pp from a year earlier.
  • Total debt increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total debt keeps falling in the next quarterly balance sheet after a -18.9% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$6.23M+7.5% QoQ
Last fiscal yearDec 2025
$6.49M+68.0% YoY
Year agoJun 2025
$7.68M-18.9% since
Total Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-18.9%——
1 year+68.0%——
3-year CAGR+192.2%——
5-year CAGR——
10-year CAGR——

Total Debt history

USD · from the balance sheet

Latest · FY2025
6.49M USD
Year-over-year change
+68.0%
4-year CAGR
+79.8%

Total Debt vs competitors

How GPCR compares with its peers on the latest reported figures

  • GPCR's Jun 2026 total debt of $6.23M is the 5th highest of the 8 companies compared; the peer median is $10.22M.
  • Its year-over-year change of -18.9% is the 3rd highest of 6, against a peer median of -60.9%.
  • Total debt amounts to 0.4% of total assets for GPCR, versus a peer median of 2.7%.
GPCR Competitors Peer median
Total Debt for GPCR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
MLYSMineralys Therapeutics, Inc.Jun 2026$97.62M ——14.6%
MAZEMaze Therapeutics, Inc.Mar 2026$61.22M +137.1%-10.1%14.6%
SEPNSepterna, Inc.Sep 2026$21.99M -8.8%+221.6%3.6%
KLRAKailera Therapeutics, Inc.Jun 2026$10.22M ——0.8%
GPCRStructure Therapeutics Inc.Jun 2026$6.23M -18.9%+192.2%0.4%
BIOABioAge Labs, Inc.Mar 2026$4.03M -60.9%+31.1%1.0%
BMEABiomea Fusion, Inc.Mar 2026$1.24M -84.4%-11.4%2.7%
VTVTvTv Therapeutics Inc.Mar 2026$0 -100.0%—0.0%
Peer median (excluding GPCR) $10.22M-60.9%+10.5%2.7%

Competitors are the stored peer set for GPCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents105.31M26.09M129.79M169.51M799.62M
Short-term Investments2M64.75M337.53M714.01M646.57M
Net Receivables00000
Inventory00000
Other Current Assets02.25M6.29M7.69M124.11M
Total Current Assets109.25M93.09M473.61M891.21M1.57B
Property, Plant & Equipment (Net)1.79M1.29M8.36M7.01M12.9M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets111K3.46M45K5.11M717K
Total Non-current Assets1.91M4.76M8.41M12.12M13.62M
Total Assets111.16M97.85M482.02M903.33M1.58B
Account Payables3.48M6.01M4.74M8.02M13.86M
Short-term Debt00000
Tax Payables231K174K356K00
Deferred Revenue00000
Other Current Liabilities1.94M3.54M4.33M7.29M12.43M
Total Current Liabilities8.66M13.01M24.74M36.02M63.29M
Long-term Debt00003.61M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities166.96M199.98M298K302K647K
Total Non-current Liabilities167.23M199.98M4.31M2.47M4.26M
Total Liabilities175.89M212.99M29.05M38.49M67.54M
Common Stock1K1K14K17K21K
Retained Earnings(64.74M)(116.95M)(206.57M)(329.1M)(470.3M)
Accumulated OCI0(110K)521K914K1.05M
Other Stockholders Equity00000
Minority Interest00000
Total Equity(64.74M)(115.14M)452.97M864.84M1.52B
Total Debt621K260K5.45M3.86M6.49M
Net Debt(104.68M)(25.83M)(124.34M)(165.65M)(793.14M)

Structure Therapeutics Inc.

NASDAQ:GPCR

Intrinsic Alpha fair value

Locked

Current Price

$17.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.